Revolution Medicines, Inc.
General ticker "RVMD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $7.8B (TTM average)
Revolution Medicines, Inc. follows the US Stock Market performance with the rate: 52.5%.
Estimated limits based on current volatility of 1.9%: low 75.81$, high 78.68$
Factors to consider:
- Total employees count: 534 (+41.3%) as of 2024
- Top business risk factors: Limited operating history, Product development delays, Cybersecurity threats, Strategic risks and growth management, Disaster recovery
- Current price 25.7% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [26.63$, 62.45$]
- 2025-12-31 to 2026-12-31 estimated range: [17.81$, 44.25$]
Financial Metrics affecting the RVMD estimates:
- Negative: with PPE of -12.3 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -7.57 <= 0.33
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
- Positive: -14.38 < Investing cash flow per share per price, % of -7.53
- Positive: Shareholder equity ratio, % of 88.54 > 63.39
Short-term RVMD quotes
Long-term RVMD plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $35.38MM | $11.58MM | $0.00MM |
| Operating Expenses | $293.66MM | $498.76MM | $689.52MM |
| Operating Income | $-258.28MM | $-487.19MM | $-689.52MM |
| Non-Operating Income | $9.15MM | $47.29MM | $88.68MM |
| R&D Expense | $253.07MM | $423.14MM | $592.23MM |
| Income(Loss) | $-249.12MM | $-439.89MM | $-600.85MM |
| Taxes | $-0.42MM | $-3.52MM | $-0.75MM |
| Profit(Loss)* | $-248.71MM | $-436.37MM | $-600.09MM |
| Stockholders Equity | $685.19MM | $1,826.19MM | $2,265.20MM |
| Assets | $811.93MM | $2,061.70MM | $2,558.30MM |
| Operating Cash Flow | $-224.40MM | $-350.57MM | $-557.44MM |
| Capital expenditure | $10.82MM | $7.73MM | $10.31MM |
| Investing Cash Flow | $-24.12MM | $-342.60MM | $-554.39MM |
| Financing Cash Flow | $301.43MM | $1,229.20MM | $959.41MM |
| Earnings Per Share** | $-3.08 | $-3.86 | $-3.58 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.